Seaport Therapeutics, Inc. IPO - What You Need to Know

Thinking about the Seaport Therapeutics IPO? Getting in on the ground floor of a biotech company is exciting, but these investments are like a rollercoaster. Here is the plain-English breakdown of what you need to know.

1. What does this company do?

Seaport Therapeutics develops medicines for brain and mental health conditions. Their "secret sauce" is a technology called Glyph.

Usually, when you take a pill, the liver breaks down much of the medicine before it reaches your bloodstream. The Glyph platform attaches a lipid molecule to the drug, allowing it to travel through the body’s lymphatic system instead. This helps the body absorb the medicine better and may reduce side effects caused by high drug concentrations in the liver.

2. What is their "pipeline"?

They are testing several programs using the Glyph platform:

• GlyphAllo (SPT-300): A treatment for major depression. They are currently running a Phase 2a study, with results expected in early 2027.
• GlyphAgo (SPT-320): A treatment for anxiety. They expect to report results from a Phase 2a study by the end of 2028.
• Glyph2BLSD (SPT-348): An early-stage program using a non-hallucinogenic version of a psychedelic compound to treat mood disorders.

3. How do they make money?

Seaport is a pre-revenue company. They do not sell any products and do not expect to make a profit for the foreseeable future. Their focus is entirely on research.

The company spun out of PureTech Health in 2024. They have an accumulated loss of $114 million. In 2025, they lost $75 million. While they have $233 million in cash, they admit this is not enough to finish developing their drugs. They will need to raise more money by selling more shares or taking on debt, which will reduce your ownership percentage.

4. Who is running the show?

CEO Daphne Zohar and Head of R&D Dr. Steven Paul lead the team. They previously worked at Karuna Therapeutics, where they helped develop a breakthrough schizophrenia drug that sold to Bristol Myers Squibb for $14 billion. While this team has a strong track record, past success does not guarantee future results.

5. What are the main risks?

Biotech investing is high-risk:

• Clinical Trial Success: The company’s value depends entirely on its drug trials. If a trial fails, the stock price could drop significantly.
• Cash Burn: The company spends money faster than it makes it. They will need to issue more shares to stay afloat, which dilutes your investment.
• Regulatory Hurdles: The FDA must approve all drugs. They may demand more studies or reject the drugs entirely, which would delay or kill the company’s plans.
• Operational Uncertainty: The company must successfully enroll patients, manufacture drugs at scale, and manage supply chains. Any failure here could cause major delays.

6. The Details

• Ticker: "SPTX" on the Nasdaq.

A final piece of advice: Biotech IPOs are speculative. Only invest money you are comfortable losing. Even the best teams face setbacks in the lab. Before you buy, ask yourself if you are comfortable with the long wait times for clinical results (2027 and 2028) and the high likelihood that the company will need to ask shareholders for more money in the future.

Disclaimer: I am an AI, not a financial advisor. This guide is for informational purposes only and does not constitute financial advice. Always do your own research or consult with a qualified professional before investing.